Patrick J. Roberts
137 works · 6,886 citations · h-index 26
Top works
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- KRAS Mutation: Should We Test for It, and Does It Matter?
- Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification
- Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
- Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
- CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury
- Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma
- Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
- INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
- CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
- Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- Clinical use of crizotinib for the treatment of non-small cell lung cancer